Rallybio Corporation RLYB
Rallybio Corporation (Nasdaq: RLYB) is an immunology/inflammation drug developer. Its lead program, RLYB116, is in Phase 1 for Complement dysregulation diseases.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RLYB212 | Fetal and neonatal alloimmune thrombocytopenia (FNAIT) | antibody | Phase 2 |
| RLYB116 | Complement-related diseases | small molecule | Phase 1 |
| RLYB332 | Diseases of iron overload | antibody | Pre-clinical |
Recent results and decisions
- Jun 1, 2026positive AVZO-1418 Phase 1 monotherapy: 5 responders among 18 efficacy-evaluable patients and 4 of 10 in NSCLC; no Grade 3+ neutropenia at 4.5 mg/kg Q2W or below (data cut May 13, 2026).
In 18 efficacy evaluable patients, 9 remain on treatment including 5 responders
Filing - Jun 1, 2026positive AVZO-023 plus fulvestrant Phase 1 dose escalation: early efficacy signs at 100 mg BID with 5 of 6 patients still on treatment; 1 DLT at 100 mg BID.
AVZO-023 + Fulvestrant ORION-1 Phase 1 Dose-Escalation Encouraging Signs of Efficacy in HR+/HER2- Breast Cancer at 100 mg BID (N=6)
Filing - Mar 2, 2026positive Candid's Phase 1 myasthenia gravis study showed robust early responses in refractory patients (average QMG change -19.3 at 16 weeks in first dose group, MG-ADL -6.7), data as of Feb 2, 2026.
Early cohorts show robust and consistent clinical response in refractory patients
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.